Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

[1]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[2]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[3]  M. Post.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2011 .

[4]  Graham G. Giles,et al.  Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer , 2010, Cancer Prevention Research.

[5]  F. McKeon,et al.  High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression , 2010, Modern Pathology.

[6]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[7]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[8]  Samuel Leung,et al.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2010, The American journal of surgical pathology.

[9]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Matt van de Rijn,et al.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.

[11]  A. Parwani.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma , 2009 .

[12]  R. Soslow,et al.  Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[14]  Kathleen R. Cho,et al.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.

[15]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[16]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. du Bois,et al.  Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. , 2005, Gynecologic oncology.

[18]  R. Young,et al.  Transitional Cell Carcinoma of the Ovary: A Morphologic Study of 100 Cases With Emphasis on Differential Diagnosis , 2004, The American journal of surgical pathology.

[19]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[20]  A. Whittemore,et al.  Histopathology, FIGO Stage, and BRCA Mutation Status of Ovarian Cancers from the Gilda Radner Familial Ovarian Cancer Registry , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  A. Folpe,et al.  Immunoprofile of Ovarian Tumors With Putative Transitional Cell (Urothelial) Differentiation Using Novel Urothelial Markers: Histogenetic and Diagnostic Implications , 2003, The American journal of surgical pathology.

[22]  T. Soussi,et al.  Lack of HIN-1 Methylation Defines Specific Breast Tumor Subtypes Including Medullary Carcinoma of the Breast and BRCA1-Linked Tumors , 2003, Cancer biology & therapy.

[23]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[24]  B. Modan,et al.  Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[26]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[27]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  G E Tomlinson,et al.  BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.

[29]  G. Giles,et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[30]  E. Venkatraman,et al.  BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.

[31]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[32]  F. Couch,et al.  Mutations of the BRCA2 gene in ovarian carcinomas. , 1996, Cancer research.

[33]  M. King,et al.  Mutation analysis of the BRCA1 gene in ovarian cancers. , 1995, Cancer research.

[34]  E. Atkinson,et al.  Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. , 1993, American journal of obstetrics and gynecology.

[35]  N. Ordóñez,et al.  Transitional cell carcinoma in high‐grade high‐stage ovarian carcinoma. An indicator of favorable response to chemotherapy , 1989, Cancer.